10-Hydroxycamptothecin (HCPT) Nanosuspensions Stabilized by MPEG-HCPT Conjugate: High Stabilizing Efficiency and Improved Antitumor Efficacy

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2017 May 30

PMID 28553107

Citations 12

Authors

Linjie Yang

Jingyi Hong

Jing Di

Yifei Guo

Meihua Han

Meifeng Liu

Xiangtao Wang

Affiliations

Soon will be listed here.

Abstract

In this study, polyethylene glycol (PEG)ylated 10-hydroxycamptothecin (mPEG-HCPT) was synthesized and used as a stabilizer to prepare 10-hydroxycamptothecin (HCPT) nanosuspensions for their in vitro and in vivo antitumor investigation. The resultant HCPT nanosuspensions (HCPT-NSps) had a very high drug payload of 94.90% (w/w) and a mean particle size of 92.90±0.20 nm with narrow size distribution (polydispersity index of 0.16±0.01). HCPT-NSps could be lyophilized without the need of the addition of any cryoprotectant and then be reconstituted into nanosuspensions of a similar size by direct resuspension in water. HCPT was in crystalline form in HCPT-NSps. Using mPEG-HCPT as stabilizer, insoluble camptothecin and 7-ethyl-10-hydroxycamptothecin could also be easily made into nanosuspensions with similar features such as high drug payload, small particle size, and cryoprotectant-free freeze drying. The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay indicated that the HCPT-NSps had a significantly higher cytotoxicity than HCPT injections, with 3.77 times lower IC value against HepG2 cells and 14.1 times lower IC value against MCF-7 cells. An in vivo study in H22 tumor-bearing mice after intravenous injection of HCPT-NSps demonstrated that HCPT-NSps significantly improved the antitumor efficacy compared to the commercially available HCPT injections (86.38% vs 34.97%) at the same dose of 5 mg/kg. Even at 1/4 of the dose, HCPT-NSps could also achieve a similar antitumor efficacy to that of HCPT injections. mPEG-HCPT may be a highly efficient stabilizer able to provide camptothecin-based drugs, and probably other antitumor agents containing aromatic structure, with unique nanosuspensions or nanocrystals for improved in vivo therapeutic efficacy.

Citing Articles

Herbal Medicine Nanocrystals: A Potential Novel Therapeutic Strategy.

Guo M, Qin S, Wang S, Sun M, Yang H, Wang X Molecules. 2023; 28(17).

PMID: 37687199 PMC: 10489021. DOI: 10.3390/molecules28176370.

Functionalized nanoparticles crossing the brain-blood barrier to target glioma cells.

Wu Y, Qian Y, Peng W, Qi X PeerJ. 2023; 11:e15571.

PMID: 37426416 PMC: 10327649. DOI: 10.7717/peerj.15571.

Advances in Antitumor Nano-Drug Delivery Systems of 10-Hydroxycamptothecin.

Chen Y, Wang Z, Wang X, Su M, Xu F, Yang L Int J Nanomedicine. 2022; 17:4227-4259.

PMID: 36134205 PMC: 9482956. DOI: 10.2147/IJN.S377149.

A Water-Soluble Polyacid Polymer Based on Hydrophilic Metal-Organic Frameworks Using Amphoteric Carboxylic Acid Ligands as Linkers for Hydroxycamptothecin Loading and Release In Vitro.

Shi Y, Liu W, Wu X, Zhu J, Zhou D, Liu X Nanomaterials (Basel). 2021; 11(11).

PMID: 34835619 PMC: 8618358. DOI: 10.3390/nano11112854.

A GSH-Responsive Nanoprodrug System Based on Self-Assembly of Lactose Modified Camptothecin for Targeted Drug Delivery and Combination Chemotherapy.

Hou C, Ma N, Shen Z, Chi G, Chao S, Pei Y Int J Nanomedicine. 2020; 15:10417-10424.

PMID: 33376329 PMC: 7764549. DOI: 10.2147/IJN.S276470.

References

Yang X, Li L, Wang Y, Tan Y . Preparation, pharmacokinetics and tissue distribution of micelles made of reverse thermo-responsive polymers. Int J Pharm. 2008; 370(1-2):210-5. DOI: 10.1016/j.ijpharm.2008.11.028. View

Zu Y, Meng L, Zhao X, Ge Y, Yu X, Zhang Y . Preparation of 10-hydroxycamptothecin-loaded glycyrrhizic acid-conjugated bovine serum albumin nanoparticles for hepatocellular carcinoma-targeted drug delivery. Int J Nanomedicine. 2013; 8:1207-22. PMC: 3615927. DOI: 10.2147/IJN.S40493. View

Kakran M, Shegokar R, Sahoo N, Al Shaal L, Li L, Muller R . Fabrication of quercetin nanocrystals: comparison of different methods. Eur J Pharm Biopharm. 2011; 80(1):113-21. DOI: 10.1016/j.ejpb.2011.08.006. View

Hertzberg R, Caranfa M, Holden K, Jakas D, Gallagher G, Mattern M . Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem. 1989; 32(3):715-20. DOI: 10.1021/jm00123a038. View

Pu X, Sun J, Wang Y, Wang Y, Liu X, Zhang P . Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int J Pharm. 2009; 379(1):167-73. DOI: 10.1016/j.ijpharm.2009.05.062. View

Hong M, Zhu S, Jiang Y, Tang G, Sun C, Fang C . Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles. J Control Release. 2009; 141(1):22-9. DOI: 10.1016/j.jconrel.2009.08.024. View

Zhao Y, Liu D, Liang W, Ye Z . In-vivo pharmacokinetics, tissue distribution and anti-tumour effect of hydroxycamptothecin delivered in oil-in-water submicron emulsions. J Pharm Pharmacol. 2012; 64(6):783-91. DOI: 10.1111/j.2042-7158.2012.01484.x. View

Zhou Y, Du Y, Wang L, Yuan H, Zhou J, Hu F . Preparation and pharmacodynamics of stearic acid and poly (lactic-co-glycolic acid) grafted chitosan oligosaccharide micelles for 10-hydroxycamptothecin. Int J Pharm. 2010; 393(1-2):143-51. DOI: 10.1016/j.ijpharm.2010.04.025. View

Greenwald R, Choe Y, Wu D . Selective phenolic acylation of 10-hydroxycamptothecin using poly (ethylene glycol) carboxylic acid. Bioorg Med Chem Lett. 2003; 13(3):577-80. DOI: 10.1016/s0960-894x(02)00926-5. View

10.

Pasut G, Veronese F . PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev. 2009; 61(13):1177-88. DOI: 10.1016/j.addr.2009.02.010. View

11.

Fleming A, Haverstick K, Saltzman W . In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain. Bioconjug Chem. 2004; 15(6):1364-75. DOI: 10.1021/bc034180o. View

12.

Li Y, Wei P, Li J, Li L . Pharmacokinetic analysis and optimization of hydroxycamptothecin-loaded nanoparticles for liver targeting. Drug Dev Ind Pharm. 2011; 38(7):837-47. DOI: 10.3109/03639045.2011.630393. View

13.

Zhao Y, Hua H, Chang M, Liu W, Zhao Y, Liu H . Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions. Int J Pharm. 2010; 392(1-2):64-71. DOI: 10.1016/j.ijpharm.2010.03.027. View

14.

Yang L, Jiang J, Hong J, Di J, Liao Y, Kuang H . High Drug Payload 10-Hydroxycamptothecin Nanosuspensions Stabilized by Cholesterol-PEG: In Vitro and In Vivo Investigation. J Biomed Nanotechnol. 2015; 11(4):711-21. DOI: 10.1166/jbn.2015.2050. View

15.

He X, Lu W, Jiang X, Cai J, Zhang X, Ding J . Synthesis and biological evaluation of bis and monocarbonate prodrugs of 10-hydroxycamptothecins. Bioorg Med Chem. 2004; 12(15):4003-8. DOI: 10.1016/j.bmc.2004.06.003. View

16.

Qu J, Shao H, Jing G, Huang F . PEG-chitosan-coated iron oxide nanoparticles with high saturated magnetization as carriers of 10-hydroxycamptothecin: preparation, characterization and cytotoxicity studies. Colloids Surf B Biointerfaces. 2012; 102:37-44. DOI: 10.1016/j.colsurfb.2012.08.004. View

17.

Zhu H, Cao J, Cui S, Qian Z, Gu Y . Enhanced tumor targeting and antitumor efficacy via hydroxycamptothecin-encapsulated folate-modified N-succinyl-N'-octyl chitosan micelles. J Pharm Sci. 2013; 102(4):1318-32. DOI: 10.1002/jps.23470. View

18.

Zhang L, Hu Y, Jiang X, Yang C, Lu W, Yang Y . Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Control Release. 2004; 96(1):135-48. DOI: 10.1016/j.jconrel.2004.01.010. View

19.

Zhang H, Hollis C, Zhang Q, Li T . Preparation and antitumor study of camptothecin nanocrystals. Int J Pharm. 2011; 415(1-2):293-300. DOI: 10.1016/j.ijpharm.2011.05.075. View

20.

Shen Y, Jin E, Zhang B, Murphy C, Sui M, Zhao J . Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery. J Am Chem Soc. 2010; 132(12):4259-65. DOI: 10.1021/ja909475m. View